Objective:

To assess the causal relationship between statin therapy and adverse effects listed in product labels using a large individual participant data meta-analysis.

Key Findings:

• Only 4 of 66 additional adverse outcomes showed statistically significant excess risk: abnormal liver transaminases, liver function test abnormalities, urinary composition alteration, and edema, but the overall evidence suggests many listed effects may be unfounded.
• Absolute annual excess risks for these outcomes were small, less than 0.1% per year, indicating minimal clinical significance.
• No significant excess risk was found for 62 outcomes, including cognitive impairment and depression, which are often cited in statin product labels.

Interpretation:

The findings suggest that many adverse effects listed in statin product labels are not supported by robust evidence, indicating a need for label revisions to enhance patient safety and inform clinical guidelines.

Limitations:

• Outcomes derived from adverse event reports may underestimate liver function test abnormalities and other potential adverse effects.
• Trials may not capture very rare adverse effects or events emerging beyond follow-up durations, which could affect the overall assessment of statin safety.
• Variation in data collection methods across trials may limit outcome assessment and introduce bias.

Conclusion:

The study highlights the need for regulatory authorities to revise statin labels to reflect accurate information, aiding informed decision-making for clinicians and patients.